Prevention. Aspirin in primary prevention--good news and bad news.

Journal article

The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.

Authors: Hennekens, C; Baigent, C

• Publication status: Published
• Journal: Nature reviews. Cardiology
• Volume: 9
• Issue: 5
• Pages: 262-263
• Publication date: 2012-05-01
• DOI: 10.1038/nrcardio.2012.26
• EISSN: 1759-5010
• ISSN: 1759-5002
• Language: English
• Keywords: Cyclooxygenase Inhibitors; Humans; Primary Prevention; Aspirin; Risk Factors; Cardiovascular Diseases